The corporate venture capital fund of a large insurance provider is looking to make private investments in the healthcare space ranging from $5 – $15 million in stages ranging anywhere from seed to buyout. The firm looks to invest in companies of strategic interest to its parent also seeking strong financial returns. The firm is willing to look at opportunities around the globe.

Within the Healthcare the firm is looking to invest in sectors of Healthcare IT, Services, and Diagnostics and to a lesser extent wearable devices. The firm is most interested in companies that are have reached or are very near FDA approval and are targeting large market indications.

The firm is looking for companies with experienced management teams and prefer working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and is open to either lead or co-invest in rounds. The firm generally looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm that was formed in 2001 to manage the capital of a successful entrepreneur and a concentrated, select group of other individuals and institutions is seeking to invest into privately held companies in the life science space. Because of the firm’s capital base, they have the ability to be highly flexible and move quickly with investment opportunities. The firm is currently focused on acquiring or investing in outstanding companies, co-investing with debt or equity sponsors, and committing capital to established third-party managers in the private and public markets. The firm can be flexible in terms of investment size and is open to reviewing opportunities from around the globe.

Within the Life Science space, the firm is primarily focused on companies in the healthcare and pharmaceutical services space where the firm has significant experience and expertise. That being said the firm is also open to reviewing early stage companies developing therapeutics, medical device, diagnostics and laboratory equipment. The firm is opportunistic across technology types and indications for these opportunities and will consider companies with products in pre-clinical stage of development to those that already have a product on the market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global pharmaceutical company is looking to form partnerships with small biotech companies using a variety of structures depending on the needs of the opportunity, including licensing, development partnerships, co-marketing, and acquisitions.  Partnerships may also involve in-kind services.  The firm works with partners worldwide.

The firm is currently looking opportunistically at novel therapeutic assets.  While the firm will consider assets in any indication area, immuno-oncology is an area of high interest; the firm is also particularly interested in other areas of immunology and in inflammation, metabolic disease (particularly type 2 diabetes), fibrosis and hypertension. The firm is open to any type of modality, including small molecules, biologics or cell therapies. The firm also has some interest in companion diagnostics and means of selecting suitable patients or monitoring patients. The firm will work with companies at any stage of development, from very early discoveries through to market.

The firm does not work with companies pursuing incremental innovations; the firm only partners on novel, breakthrough technologies, such as new molecules or new targets. The firm is interested in assets in which the mechanism of action is understood, and it is preferred that the target or pathway of the asset is validated. The firm is interested in assets that have been shown to have an unambiguous advantage, and which can create value for patients and payers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US based Venture Capital firm is currently looking to make investments from a $125 million with up to 20% of the committed capital going to seed and early stage companies and projects. The firm typically invests between $2 and $4 million initially and $6 million to 10$ million over the lifetime of the investment. Investments are generally in the form of milestone based equity tranches, however the firm also has experience in working with convertible notes. The firm is looking to make 4-6 allocation in the next 6-9 months throughout the United States however they are focused on companies in the Southeast.

The firm is currently looking for early stage companies in the Therapeutics, Diagnostics, Medical Technology and HealthCare IT spaces. In the Therapeutics space the firm is opportunistic in terms of subsector but is most interested in indications of Ophthalmology, Cardiovascular, Pulmonary, Anti-Infectives, Metabolic Disorders, Renal Diseases, Oncology, Immunology, Dermatology, and Orphan Diseases. For companies developing therapeutics the firm is looking for companies primarily with a lead product in preclinical trials although they will consider companies with products having recently entered Phase I. The firm also has generally stayed away from and is not currently seeking companies working with Regenerative Medicine and Wound Care.  In the Medical Technology space the firm strongly prefers that the company have at least have an early prototype of their product and the firm is opportunistic in terms of device subsector.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com